Exposure–response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters

PURPOSE: The phase III trial of pertuzumab plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus docetaxel for first-line treatment of HER2-positive metastatic breast cancer included a substudy to determine whether pertuzumab affected the corrected QT (QTc) interval or other electroca...

Descripción completa

Detalles Bibliográficos
Autores principales: Garg, Amit, Li, Jing, Clark, Emma, Knott, Adam, Carrothers, Timothy J., Marier, Jean-François, Cortés, Javier, Brewster, Michael, Visich, Jennifer, Lum, Bert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825499/
https://www.ncbi.nlm.nih.gov/pubmed/23999693
http://dx.doi.org/10.1007/s00280-013-2279-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825499/
https://www.ncbi.nlm.nih.gov/pubmed/23999693
http://dx.doi.org/10.1007/s00280-013-2279-6

Ejemplares similares